Effect of a test meal on meal responses of satiation hormones and their association to insulin resistance in obese adolescents

Obesity

Volumn 22, Issue 9, 2014, Pages 2047-2052

  Beglinger, Svetlana ^a   Meyer Gerspach, Anne Christin ^b   Graf, Steffi ^a   Zumsteg, Urs ^a   Drewe, Jürgen ^b   Beglinger, Christoph ^b   Gutzwiller, Jean Pierre ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; INSULIN; ISLET AMYLOID POLYPEPTIDE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; BODY MASS; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; POSTPRANDIAL STATE; SATIETY; SEX RATIO; BLOOD; BODY MASS INDEX; CHILD; CONTROLLED CLINICAL TRIAL; HUMANS; MEALS; METABOLISM; PEDIATRIC OBESITY; PHYSIOLOGY; POSTPRANDIAL PERIOD; SATIATION;

ADOLESCENT; BODY MASS INDEX; CHILD; FEMALE; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; ISLET AMYLOID POLYPEPTIDE; MALE; MEALS; METABOLIC SYNDROME X; PEDIATRIC OBESITY; POSTPRANDIAL PERIOD; SATIATION;

EID: 84906934248     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20805     Document Type: Article

References (40)

1. Cummings DE, Overduin J,. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13-23.
2. Levy-Marchal C, Arslanian S, Cutfield W, et al. Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 2010; 95: 5189-5198.
3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K,. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
4. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
5. Erdmann J, Topsch R, Lippl F, Gussmann P, Schusdziarra V,. Postprandial response of plasma ghrelin levels to various test meals in relation to food intake, plasma insulin, and glucose. J Clin Endocrinol Metab 2004; 89: 3048-3054.
6. Ariyasu H, Takaya K, Hosoda H, et al. Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 2002; 143: 3341-3350.
7. Lomenick JP, Clasey JL, Anderson JW,. Meal-related changes in ghrelin, peptide YY, and appetite in normal weight and overweight children. Obesity 2008; 16: 547-552.
8. Maffeis C, Bonadonna RC, Consolaro A, et al. Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children. Eur J Endocrinol 2006; 154: 61-68.
9. Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005; 90: 2161-2168.
10. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81-86.
11. Brubaker PL,. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann NY Acad Sci 2006; 1070: 10-26.
12. Rask E, Olsson T, Soderberg S, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24: 1640-1645.
13. Reinehr T, de Sousa G, Roth CL,. Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. J Pediatr Gastroenterol Nutr 2007; 44: 608-612.
14. Reda TK, Geliebter A, Pi-Sunyer FX,. Amylin, food intake, and obesity. Obes Res 2002; 10: 1087-1091.
15. Lutz TA, Geary N, Szabady MM, Del Prete E, Scharrer E,. Amylin decreases meal size in rats. Physiol Behav 1995; 58: 1197-1202.
16. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838-848.
17. Gulli G, Rossetti L, DeFronzo RA,. Hyperamylinemia is associated with hyperinsulinemia in the glucose-tolerant, insulin-resistant offspring of two Mexican-American non-insulin-dependent diabetic parents. Metabolism 1997; 46: 1157-1161.
18. Roth CL, Bongiovanni KD, Gohlke B, Woelfle J,. Changes in dynamic insulin and gastrointestinal hormone secretion in obese children. J Pediatr Endocrinol Metab 2010; 23: 1299-1309.
19. Paulsson JF, Westermark GT,. Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 2005; 54: 2117-2125.
20. Pipeleers DG, Schuit FC, in't Veld PA, et al. Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology 1985; 117: 824-833.
21. Dunning BE, Gerich JE,. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-283.
22. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
23. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-185.
24. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI,. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-1327.
25. Mittelman SD, Klier K, Braun S, Azen C, Geffner ME, Buchanan TA,. Obese adolescents show impaired meal responses of the appetite-regulating hormones ghrelin and PYY. Obesity 2010; 18: 918-925.
26. Tomasik P, Sztefko K, Starzyk J,. Entero-insular axis in children with simple obesity. Pediatr Endocrinol Diabetes Metab 2009; 15: 63-69.
27. Lugari R, Dell'Anna C, Ugolotti D, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 2000; 32: 424-428.
28. Martins C, Kulseng B, King NA, Holst JJ, Blundell JE,. The effects of exercise-induced weight loss on appetite-related peptides and motivation to eat. J Clin Endocrinol Metab 2010; 95: 1609-1616.
29. George L, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S,. Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab 2011; 96: 2136-2145.
30. Cherrington AD,. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999; 48: 1198-1214.
31. Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD,. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 1997; 273 (Part 1): E488-E496.
32. Jamison RA, Stark R, Dong J, et al. Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am J Physiol Endocrinol Metab 2011; 301: E1174-E1183.
33. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51: 636-641.
34. Gedulin BR, Rink TJ, Young AA,. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997; 46: 67-70.
35. Mather KJ, Paradisi G, Leaming R, et al. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev 2002; 18: 118-126.
36. Smith D, Mamo JC,. Islet amyloid polypeptide (amylin) modulates chylomicron metabolism in rats. Clin Exp Pharmacol Physiol 2000; 27: 345-351.
37. Montane J, Klimek-Abercrombie A, Potter KJ, Westwell-Roper C, Bruce Verchere C,. Metabolic stress, IAPP and islet amyloid. Diabetes Obes Metab 2012; 14 (Suppl 3): 68-77.
38. Naslund E, Gryback P, Backman L, et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43: 945-952.
39. Egan JM, Bulotta A, Hui H, Perfetti R,. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003; 19: 115-123.
40. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158.